Novel advances in parainfluenza virus 3 neutralization through antibodies targeting hemagglutinin-neuraminidase.

Abstract Parainfluenza virus 3 (PIV3) remains to be a global burden infants, the elderly, and immunocompromised individuals. With no approved therapeutics or vaccines, PIV3 continues cause large portion of lower respiratory illness hospitalizations in young children. Similar other paramyxoviruses, utilizes two structural proteins, fusion (F) protein hemagglutinin-neuraminidase (HN) protein, for viral entry. Here, we characterize newly identified human monoclonal antibodies (mAbs) targeting HN on virion, with EC 50values ranging from 9ng/mL 21ng/mL. The mAbs were tested neutralization all determined have an IC 11ng/mL 450ng/mL. Utilizing biolayer interferometry, conducted competitive epitope mapping study found targeted three major epitopes some binding between multiple sites, suggesting these are within close proximity each other. one particular site had significantly low 120ng/mL. We established infection model Golden Syrian hamsters currently testing prevention replication lungs airways. Due similarities amongst different parainfluenza subtypes, plan potential cross-neutralizing capabilities against subtypes. Supported by grants NIH (R01 AI143865)